Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: A randomized study

Seminars in Oncology

Volumn 24, Issue 4 SUPPL.12, 1997, Pages

  Kosmidis, P ^a   Mylonakis, N ^a   Fountzilas, G ^a   Samantas, E ^a   Athanassiadis, A ^a   Pavlidis, N ^a   Skarlos, D ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; NEUTROPENIA; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0030768321     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)